Rhythm Pharmaceuticals Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 11.4% | 50.0% | 21.6% | 13.0% | 15.4% | 4.2% | 11.6% | 11.7% | 12.4% | 11.6% | 10.7% | 13.3% | 10.8% | 10.1% | 11.5% | 9.1% | 11.2% | 11.4% | 10.7% | 8.4% | 11.9% | 12.5% | 11.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 88.6% | 50.0% | 78.4% | 87.0% | 84.6% | 95.8% | 88.4% | 88.3% | 87.6% | 88.4% | 89.3% | 86.7% | 89.2% | 89.9% | 88.5% | 90.9% | 88.8% | 88.6% | 89.3% | 91.6% | 88.1% | 87.5% | 89.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 56,888.6% | 9,162.0% | 2,678.9% | 1,737.7% | 2,170.2% | 347.0% | 492.9% | 267.9% | 330.8% | 174.5% | 149.2% | 123.3% | 494.8% | 103.2% | 114.1% | 98.4% | 113.1% | 87.2% | 89.7% | 73.4% | 69.4% | 60.9% | 72.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 37,482.9% | 5,644.2% | 1,703.0% | 1,155.5% | 1,431.8% | 246.3% | 512.1% | 299.4% | 214.8% | 156.3% | 135.4% | 133.6% | 132.4% | 125.2% | 106.4% | 91.2% | 119.5% | 94.7% | 102.2% | 100.4% | 105.8% | 94.7% | 100.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 98,368.6% | 14,806.2% | 4,381.9% | 2,893.2% | 3,602.1% | 593.2% | 1,005.0% | 567.3% | 545.6% | 330.8% | 284.6% | 256.9% | 627.9% | 229.1% | 220.5% | 189.6% | 232.6% | 182.0% | 191.9% | 173.8% | 175.2% | 155.6% | 172.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -98,280.0% | -14,756.2% | -4,303.5% | -2,806.2% | -3,517.4% | -497.4% | -916.6% | -479.0% | -458.0% | -242.5% | -195.3% | -170.3% | -538.7% | -139.2% | -132.0% | -98.6% | -143.7% | -93.4% | -102.6% | -82.2% | -87.1% | -68.1% | -83.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 4.9% | 0.5% | 50.0% | 34.3% | 26.7% | 17.2% | 14.0% | 18.8% | 18.3% | 15.8% | 15.8% | 13.0% | 16.5% | 12.0% | 9.2% | 8.1% | 7.6% | 6.4% | 7.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 187,874.3% | -14,748.5% | -4,290.1% | -2,798.8% | -3,522.3% | -496.4% | -953.8% | -483.4% | -455.0% | -243.0% | -194.6% | -171.0% | -543.3% | -109.3% | -132.3% | -103.7% | -151.1% | -95.4% | -102.9% | -83.0% | -91.7% | -68.6% | -85.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 62,874.3% | -1,832.8% | -875.0% | -439.7% | 4.9% | -1.0% | 37.2% | 4.4% | -3.1% | 0.4% | 1.6% | 0.8% | 1.2% | 1.6% | -1.0% | -0.2% | 0.2% | 0.7% | 0.2% | -0.1% | 0.9% | 0.6% | 0.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 125,000.0% | -12,915.7% | -3,415.1% | -2,359.2% | -3,522.3% | -496.4% | -953.8% | -483.4% | -455.0% | -243.0% | -196.2% | -171.8% | -544.4% | -110.9% | -131.2% | -103.5% | -151.4% | -96.1% | -103.1% | -83.0% | -92.6% | -69.2% | -85.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -97,705.7% | -14,632.8% | -4,259.4% | -2,781.0% | -3,498.9% | -491.0% | -893.4% | -444.1% | -424.3% | -223.5% | -178.7% | -150.5% | -523.4% | -92.1% | -115.4% | -89.8% | -133.4% | -82.7% | -93.1% | -74.5% | -83.6% | -61.8% | -77.0% |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.